"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 3 | 6 |
| 1995 | 1 | 0 | 1 |
| 1996 | 3 | 2 | 5 |
| 1997 | 3 | 7 | 10 |
| 1998 | 2 | 4 | 6 |
| 1999 | 2 | 8 | 10 |
| 2000 | 3 | 11 | 14 |
| 2001 | 3 | 11 | 14 |
| 2002 | 9 | 5 | 14 |
| 2003 | 6 | 12 | 18 |
| 2004 | 12 | 14 | 26 |
| 2005 | 13 | 10 | 23 |
| 2006 | 16 | 13 | 29 |
| 2007 | 14 | 14 | 28 |
| 2008 | 24 | 17 | 41 |
| 2009 | 21 | 25 | 46 |
| 2010 | 14 | 20 | 34 |
| 2011 | 25 | 29 | 54 |
| 2012 | 30 | 18 | 48 |
| 2013 | 28 | 31 | 59 |
| 2014 | 17 | 25 | 42 |
| 2015 | 31 | 31 | 62 |
| 2016 | 22 | 36 | 58 |
| 2017 | 30 | 29 | 59 |
| 2018 | 31 | 35 | 66 |
| 2019 | 51 | 31 | 82 |
| 2020 | 43 | 26 | 69 |
| 2021 | 25 | 34 | 59 |
| 2022 | 2 | 27 | 29 |
| 2023 | 0 | 19 | 19 |
| 2024 | 15 | 30 | 45 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Exploring the potential of TGFß as a diagnostic marker and therapeutic target against cancer. Biochem Pharmacol. 2025 Jan; 231:116646.
-
Metastatic renal cell carcinoma with fibromyomatous stroma associated with tuberous sclerosis or MTOR, TSC1/TSC2-Mutations: A Series of 4 cases and a review of the literature. Hum Pathol. 2024 Nov; 153:105680.
-
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.
-
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study. J Immunother Cancer. 2024 Nov 03; 12(11).
-
Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2024 Nov 01; 148(11):1251-1271.
-
5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. JCO Precis Oncol. 2024 Oct; 8:e2400277.
-
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446.
-
Characteristics of a cost-effective blood test for colorectal cancer screening. J Natl Cancer Inst. 2024 Oct 01; 116(10):1612-1620.
-
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Oct 01; 30(19):4318-4328.
-
ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era. Ann Surg Oncol. 2024 Dec; 31(13):8904-8905.